Breast Cancer Pathways: Advanced/Metastatic Disease

<table>
<thead>
<tr>
<th>Patient Name:</th>
<th>Date of Birth:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Member Number:</td>
<td>Treatment Start Date:</td>
</tr>
</tbody>
</table>

**Pathology:**

**Line of Therapy:** __1st Line__ __2nd Line__ __3rd Line__ __3rd Line+__

**Biomarkers/Characteristics:** (select all that apply)

- Estrogen Receptor (ER): __Negative__ __Positive__
- Progesterone Receptor (PR): __Negative__ __Positive__
- HER2 status by FISH/CISH: __Negative__ __Positive__ __Equivocal__ or by IHC: __0__ __1+__ __2+__ __3+
- Menopausal Status: __Pre__ __Peri__ __Post__ __N/A (patient is male__)

**Advanced/Metastatic Disease | HER2 Negative | First and Subsequent Lines of Therapy (1st Line+)**

- __Capecitabine (Xeloda)__
- __Doxorubicin (Adriamycin)__
- __Gemcitabine (Gemzar)__
- __Paclitaxel__
- __Vinorelbine (Navelbine)__

**Advanced/Metastatic Disease | HER2 Negative | Deleterious Germline BRCA Mutation | First and Subsequent Lines of Therapy (1st Line+)**

- __Olaparib (Lynparza)__

**Advanced/Metastatic Disease | HER2 Positive | First Line of Therapy (1st Line)**

- __Capecitabine (Xeloda) and trastuzumab (Herceptin)__
- __Gemcitabine (Gemzar) and trastuzumab (Herceptin)__
- __Paclitaxel and trastuzumab (Herceptin)__
- __Pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel (Taxotere)__
- __Pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel__
- __Vinorelbine (Navelbine) and trastuzumab (Herceptin)__

**Advanced/Metastatic Disease | HER2 Positive | Second and Subsequent Lines of Therapy (2nd Line+)**

- __Ado-trastuzumab emtansine (Kadcyla)__
- __Capecitabine (Xeloda) and lapatinib (Tykerb)__
- __Capecitabine (Xeloda) and trastuzumab (Herceptin)__
- __Gemcitabine (Gemzar) and trastuzumab (Herceptin)__
- __Paclitaxel and trastuzumab (Herceptin)__
- __Pertuzumab (Perjeta), trastuzumab (Herceptin), and docetaxel (Taxotere)__
- __Pertuzumab (Perjeta), trastuzumab (Herceptin), and paclitaxel__
- __Trastuzumab (Herceptin) and lapatinib (Tykerb)__
- __Trastuzumab (Herceptin) monotherapy__
- __Vinorelbine (Navelbine) and trastuzumab (Herceptin)__

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.